Dermatitis Atopic Clinical Trials

12 recruitingLast updated: May 21, 2026

There are 12 actively recruiting dermatitis atopic clinical trials across 32 countries. Studies span Phase 2, Phase 3, Not Applicable. Top locations include Taipei, Taiwan, Calgary, Alberta, Canada, Kaohsiung City, Taiwan. Updated daily from ClinicalTrials.gov.


Dermatitis Atopic Trials at a Glance

12 actively recruiting trials for dermatitis atopic are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Taipei, Calgary, and Kaohsiung City. Lead sponsors running dermatitis atopic studies include Pfizer, Sanofi, and Janssen Research & Development, LLC.

Browse dermatitis atopic trials by phase

About Dermatitis Atopic Clinical Trials

Looking for clinical trials for Dermatitis Atopic? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dermatitis Atopic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dermatitis Atopic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

DermatitisAtopic DermatitisEczema Atopic Dermatitis+5 more
Apollo Therapeutics Ltd280 enrolled85 locationsNCT07599813
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Dermatitis Atopic
Sanofi636 enrolled147 locationsNCT06241118
Recruiting
Phase 2

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Dermatitis Atopic
Janssen Research & Development, LLC180 enrolled56 locationsNCT07230860
Recruiting
Phase 2

Effects of Treatments on Atopic Dermatitis

DermatitisEczemaSkin Diseases+2 more
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)130 enrolled1 locationNCT01631617
Recruiting

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Atopic DermatitisDermatitis AtopicAtopic Dermatitis, Unspecified
Pfizer150 enrolled1 locationNCT06899204
Recruiting
Phase 2

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Dermatitis Atopic
Sanofi901 enrolled175 locationsNCT05769777
Recruiting

A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

Dermatitis Atopic
Pfizer1,100 enrolled1 locationNCT05391061
Recruiting
Phase 3

Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis Atopic
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.180 enrolled3 locationsNCT07042126
Recruiting

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

DermatitisEczemaImmune System Diseases+3 more
Pfizer200 enrolled8 locationsNCT06353087
Recruiting
Not Applicable

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

PruritusDermatitis Atopic
Nexgen Dermatologics, Inc.60 enrolled1 locationNCT06488742
Recruiting

A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment

Dermatitis Atopic
Sanofi150 enrolled9 locationsNCT06192563
Recruiting

Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

Dermatitis Atopic
Fundación Academia Española de Dermatología2,500 enrolled9 locationsNCT05674695